ArticleInternational journal of general medicine2025
Prognostic Impact of Anemia in Patients with Significant Mitral Regurgitation: A Multicenter Cohort Study.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: Anemia may affect cardiac function and outcomes in cardiovascular diseases. However, there is scarce evidence on the impact of anemia in patients with mitral valve dysfunction. This study sought to investigate the prevalence of anemia in patients with significant mitral regurgitation (MR), as well as its association with outcomes. Methods: A total of 4339 patients with moderate or greater MR in the China Valvular Heart Disease study were included in this analysis. Anemia was determined according to the World Health Organization definition. The primary outcome of this study was two-year all-cause mortality, and the secondary outcome was the composite of death and hospitalization for heart failure. Results: Anemia was present in 33.1% (1435/4339) of the study population. During a median follow-up of 732 (704-748) days, 426 (9.8%) patients died and 686 (15.8%) experienced the composite endpoint. Both anemia and hemoglobin were independently associated with two-year outcomes (all P < 0.001). Similar results were observed in patients with conservatively managed MR, left ventricular ejection fraction ≤60%, or in subsets according to New York Heart Association functional class (I/II-IV), the diagnosis of heart failure, severity of valvular lesion, etiology of MR, and the presence of malnutrition. The combination of anemia with left atrial dilatation or impaired left ventricular systolic function identified high-risk patients with significantly poor survival, and the inclusion of anemia to EuroSCORE II model enhanced risk prediction in MR. Conclusion: Anemia was common in patients with MR, and it was a significant predictor of poor prognosis. The high prevalence and negative impact of anemia make it as an important risk factor for prognostic evaluation and clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.